Literature DB >> 15813936

Mechanisms of ATP action on motor nerve terminals at the frog neuromuscular junction.

S Grishin1, A Shakirzyanova, A Giniatullin, R Afzalov, R Giniatullin.   

Abstract

We have shown previously that ATP inhibits transmitter release at the neuromuscular junction through the action on metabotropic P2Y receptors coupled to specific second messenger cascades. In the present study we recorded K(+) or Ca(2+) currents in motor nerve endings or blocked K(+) or Ca(2+) channels in order to explore the nature of downstream presynaptic effectors. Endplate currents were presynaptically depressed by ATP. Blockers of Ca(2+)-activated K(+)-channels, such as iberiotoxin, apamin or tetraethylammonium, did not change the depressant action of ATP. By contrast, K(+) channel blocker 4-aminopyridine (4-AP) and raised extracellular Ca(2+) attenuated the effect of ATP. However, these effects of 4-AP and high Ca(2+) were reversed by Mg(2+), suggesting Ca(2+)-dependence of the ATP action. Ba(2+) promoted the depressant action of ATP as did glibenclamide, a blocker of ATP-sensitive K(+) channels, or mild depolarization produced by 7.5 mm K(+). None of the K(+) channel blockers affected the depressant action of adenosine. Focal recording revealed that neither ATP nor adenosine affected the fast K(+) currents of the motor nerve endings. However, unlike adenosine, ATP or UTP, an agonist of P2Y receptors, reversibly reduced the presynaptic Ca(2+)-current. This effect was abolished by suramin, an antagonist of P2 receptors. Depressant effect of ATP on the endplate and Ca(2+)-currents was mimicked by arachidonate, which precluded the action of ATP. ATP reduced acetylcholine release triggered by ionomycin or sucrose, suggesting inhibition of release machinery. Thus, the presynaptic depressant action of ATP is mediated by inhibition of Ca(2+) channels and by mechanism acting downstream of Ca(2+) entry.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15813936     DOI: 10.1111/j.1460-9568.2005.03976.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  8 in total

Review 1.  Interaction of P2 purinergic receptors with cellular macromolecules.

Authors:  Laszlo Köles; Zoltan Gerevich; João Felipe Oliveira; Zoltan Sandor Zadori; Kerstin Wirkner; Peter Illes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

Review 2.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

3.  Inhibition of presynaptic neurotoxins in taipan venom by suramin.

Authors:  Sanjaya Kuruppu; Janeyuth Chaisakul; A Ian Smith; Wayne C Hodgson
Journal:  Neurotox Res       Date:  2013-10-16       Impact factor: 3.911

Review 4.  100 Years of Suramin.

Authors:  Natalie Wiedemar; Dennis A Hauser; Pascal Mäser
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

5.  Reactive oxygen species contribute to the presynaptic action of extracellular ATP at the frog neuromuscular junction.

Authors:  A R Giniatullin; S N Grishin; E R Sharifullina; A M Petrov; A L Zefirov; R A Giniatullin
Journal:  J Physiol       Date:  2005-03-17       Impact factor: 5.182

Review 6.  Purinergic modulation of synaptic signalling at the neuromuscular junction.

Authors:  Keith J Todd; Richard Robitaille
Journal:  Pflugers Arch       Date:  2006-04-08       Impact factor: 3.657

Review 7.  Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF.

Authors:  Rashid Giniatullin; Andrea Nistri; Elsa Fabbretti
Journal:  Mol Neurobiol       Date:  2008-05-06       Impact factor: 5.590

8.  ATP Reduces the Entry of Calcium Ions into the Nerve Ending by Blocking L-type Calcium Channels.

Authors:  E F Khaziev; D V Samigullin; A N Tsentsevitsky; E A Bukharaeva; E E Nikolsky
Journal:  Acta Naturae       Date:  2018 Apr-Jun       Impact factor: 1.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.